Mirati Therapeutics (MRTX) Tops Q3 EPS by $1.24; Reports Cash and Cash Equivalents of $1.2B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mirati Therapeutics (MRTX) Announces Proposed $500M Share Offering
November 9, 2021 4:24 PM ESTMirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions,... More
Mirati Therapeutics (MRTX) PT Raised to $235 at Stifel
November 9, 2021 7:13 AM ESTStifel analyst Ben Burnett raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $235.00 (from $202.00) while maintaining a Buy rating.
The analyst commented, "Were reiterating our Buy-rating following initial pembro+adagrasib frontline NSCLC data disclosed in conjunction with the company's 3Q21 update. The... More
